

Overview

Useful For

Monitoring propafenone therapy

Assessing potential propafenone toxicity

Method Name

Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

NY State Available

Yes

Specimen

Specimen Type

Serum Red

Specimen Required

Patient Preparation: Specimens should only be collected after patient has been receiving propafenone for at least 3 days. Trough concentrations should be collected just before administration of the next dose.

Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube: Red top (serum gel/SST are **not acceptable**)

Submission Container/Tube: Plastic vial

Specimen Volume: 1.5 mL

Collection Instructions:

1. Draw blood immediately before next scheduled dose.
2. Centrifuge and aliquot serum into a plastic vial within 2 hours of collection.

Forms

If not ordering electronically, complete, print, and send a [Therapeutics Test Request](#) (T831) with the specimen.

Specimen Minimum Volume

0.5 mL

Reject Due To

Gross hemolysis	OK
Gross lipemia	OK
Gross icterus	OK

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Serum Red	Ambient	28 days	
	Refrigerated (preferred)	28 days	
	Frozen	28 days	

Clinical & Interpretive**Clinical Information**

Propafenone (Rythmol) is a class 1C cardiac antiarrhythmic used to treat ventricular arrhythmias (ventricular tachycardia, supraventricular tachycardia, and ventricular premature contractions).

Propafenone undergoes extensive first metabolism (half-life is approximately 2-10 hours). Its clinical efficacy is maintained through the formation of a metabolite (5-hydroxypropafenone) that is more pharmacologically active than the parent drug and has a longer half-life.

Specimens should only be collected after patient has been receiving propafenone orally for at least 3 days. Trough concentrations should be collected just before administration of the next dose. The therapeutic concentration is 0.5 to 2.0 mcg/mL; concentrations less than 0.5 mcg/mL likely indicate inadequate therapy, and propafenone above 2.0 mcg/mL indicates excessive therapy. Adverse side effects are seen in the central nervous system, skin, and gastrointestinal tract.

Reference Values

Trough Value

0.5-2.0 mcg/mL: Therapeutic concentration

>2.0 mcg/mL: Toxic concentration

Interpretation

The therapeutic concentration is 0.5 to 2.0 mcg/mL; concentrations below 0.5 mcg/mL likely indicate inadequate therapy and propafenone above 2.0 mcg/mL indicates excessive therapy.

Cautions

Specimens that are obtained from gel tubes or anticoagulate collections can cause assay interference.

Clinical Reference

1. Milone MC, Shaw LM. Therapeutic drugs and their management. In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023:420-453
2. Josephson ME, Buxton AE, Marchlinski FE. The tachyarrhythmias: tachycardias. In: Wilson JD, Braunwald E, Isselbacher KJ, et al, eds. Harrison's Principles of Internal Medicine. 12th ed. McGraw-Hill Book Company; 1991:915
3. Valdes R Jr, Jortani SA, Gheorghide M. Standards of laboratory practice: cardiac drug monitoring. National Academy of Clinical Biochemistry. Clin Chem. 1998;44(5):1096-1099
4. Joseph SP, Holt DW. Electrophysiological properties of mexiletine assessed with respect to plasma concentrations. Eur J Cardiol. 1980;11(2):115-121

Performance

Method Description

Protein is precipitated from serum and following centrifugation the supernatant is diluted and analyzed by liquid chromatography tandem mass spectrometry.(Unpublished Mayo method)

PDF Report

No

Day(s) Performed

Monday through Friday

Report Available

2 to 5 days

Specimen Retention Time

14 days

Performing Laboratory Location

Rochester

Fees & Codes

Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

80299

LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
PFN	Propafenone, S	6905-4

Result ID	Test Result Name	Result LOINC® Value
80295	Propafenone, S	6905-4